Evidence map›Paper›PMID 37435781›Full record

ReviewHematological oncology2024

Diffuse large B-cell lymphoma.

Allison Barraclough, Eliza Hawkes, Laurie H Sehn, Sonali M Smith

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematological oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Expression and diagnostic significance of plasma exosomal RNA in diffuse large B-cell lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. [Case of concurrent second branchial cleft cyst and diffuse large B-cell lymphoma].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Allison BarracloughDepartment of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Eliza HawkesOlivia Newton John Cancer Research Centre, Austin Health, Melbourne, Victoria, Australia.
Laurie H SehnBC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, British Columbia, Canada.
Sonali M SmithThe University of Chicago Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-9893-4949

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large B-cell lymphoma, the prototype of aggressive non-Hodgkin lymphomas, is both the most common lymphoma and accounts for the highest global burden of lymphoma-related deaths. For nearly 4 decades, the goal of treatment has been "cure", first based on CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and subsequently with rituximab plus CHOP. However, there is significant clinical, pathologic, and biologic heterogeneity, and not all patients are cured. Understanding and incorporating this biologic heterogeneity into treatment decisions unfortunately is not yet standard of care. Despite this gap, we now have significant advances in frontline, relapsed, and refractory settings. The POLARIX trial shows, for the first time, improved progression-free survival in a prospective randomized phase 3 setting. In the relapsed and refractory settings, there are now many approved agents/regimens, and several bispecific antibodies poised to join the arsenal of options. While chimeric antigen receptor T-cell therapy is discussed in detail elsewhere, it has quickly become an excellent option in the second-line setting and beyond. Unfortunately, special populations such as older adults continue to have poor outcomes and be underrepresented in trials, although a new generation of trials aim to address this disparity. This brief review will highlight the key issues and advances that offer improved outcomes to an increasing portion of patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseCyclophosphamideHumansCyclophosphamideantibody‐drug conjugatesdiffuse large B‐cell lymphomaolder adultstreatment

Identifiers

PMID37435781
PMCPMC11590043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.